AlphaTON Capital Corp

AlphaTON Capital blends orphan‑drug biotech with privacy‑focused blockchain, partnering with Midnight & Google Cloud to secure clinical data, boost compliance and unlock new investor potential.

AlphaTON Capital’s SEC Form 3 reveals CEO Brittany Kaiser owns <10% of the Nasdaq‑listed biotech, outlining ownership, volatility and future strategy.

AlphaTON Capital’s $30 million stake in Anduril and new NVIDIA B300 GPUs power Cocoon AI, diversifying from biotech into high‑growth defense tech and AI infrastructure.